AR056862A1 - 1,2-etilendiaminas sustituidas, medicamentos que contienen a estos compuestos, su uso y procedimiento para su preparacion - Google Patents

1,2-etilendiaminas sustituidas, medicamentos que contienen a estos compuestos, su uso y procedimiento para su preparacion

Info

Publication number
AR056862A1
AR056862A1 ARP060101206A ARP060101206A AR056862A1 AR 056862 A1 AR056862 A1 AR 056862A1 AR P060101206 A ARP060101206 A AR P060101206A AR P060101206 A ARP060101206 A AR P060101206A AR 056862 A1 AR056862 A1 AR 056862A1
Authority
AR
Argentina
Prior art keywords
alkyl
alkynyl
aryl
cycloalkyl
heterocyclyl
Prior art date
Application number
ARP060101206A
Other languages
English (en)
Spanish (es)
Inventor
Cornelia Dorner-Ciossek
Niklas Heine
Stefan Peters
Sandra Handschuh
Marcus Kostka
Christian Eickmeier
Technical Services Heineken
Klaus Klinder
Klaus Fuchs
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of AR056862A1 publication Critical patent/AR056862A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06017Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06017Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06191Dipeptides containing heteroatoms different from O, S, or N
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • C07K5/0802Tripeptides with the first amino acid being neutral
    • C07K5/0804Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • C07K5/0802Tripeptides with the first amino acid being neutral
    • C07K5/0812Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • C07K5/0821Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ARP060101206A 2005-03-30 2006-03-29 1,2-etilendiaminas sustituidas, medicamentos que contienen a estos compuestos, su uso y procedimiento para su preparacion AR056862A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05006939 2005-03-30

Publications (1)

Publication Number Publication Date
AR056862A1 true AR056862A1 (es) 2007-10-31

Family

ID=36545049

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060101206A AR056862A1 (es) 2005-03-30 2006-03-29 1,2-etilendiaminas sustituidas, medicamentos que contienen a estos compuestos, su uso y procedimiento para su preparacion

Country Status (7)

Country Link
US (3) US7713961B2 (https=)
EP (1) EP1866034A1 (https=)
JP (1) JP2008534541A (https=)
AR (1) AR056862A1 (https=)
CA (1) CA2603404A1 (https=)
TW (1) TW200716152A (https=)
WO (1) WO2006103038A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2603404A1 (en) * 2005-03-30 2006-10-05 Boehringer Ingelheim International Gmbh Substituted 1,2-ethylendiamines, medicaments comprising said compound; their use and their method of manufacture
CA2617294A1 (en) * 2005-08-03 2007-02-08 Boehringer Ingelheim International Gmbh Substituted ethane-1,2-diamines for the treatment of alzheimer's disease ii
US20100144681A1 (en) * 2005-08-11 2010-06-10 Klaus Fuchs Compounds for the treatment of alzheimer's disease
EP1915339A1 (de) * 2005-08-11 2008-04-30 Boehringer Ingelheim International GmbH Inhibitoren der beta-sekretase zur behandlung der alzheimer- erkrankung
CA2618019A1 (en) * 2005-08-11 2007-02-15 Boehringer Ingelheim International Gmbh Compounds for the treatment of alzheimer's disease
WO2007017510A2 (de) * 2005-08-11 2007-02-15 Boehringer Ingelheim International Gmbh Isophthalsäurediamide zur behandlung der alzheimer erkrankung
WO2010042796A1 (en) 2008-10-10 2010-04-15 Purdue Research Foundation Compounds for treatment of alzheimer's disease
US8394807B2 (en) 2008-11-20 2013-03-12 Purdue Research Foundation Quinazoline inhibitors of BACE 1 and methods of using
WO2010065861A2 (en) * 2008-12-05 2010-06-10 Purdue Research Foundation Inhibitors of bace 1 and methods for treating alzheimer's disease
US20130059840A1 (en) * 2009-10-05 2013-03-07 Comentis, Inc. Sulfonamido pyrrolidine compounds which inhibit beta-secretase activity and methods of use thereof
WO2014036105A2 (en) * 2012-08-30 2014-03-06 Oklahoma Medical Research Foundation Inhibitors of memapsin 2 cleavage for the treatment of alzheimer's disease
BR112023026747A2 (pt) 2021-06-18 2024-03-12 Aligos Therapeutics Inc Métodos e composições para direcionamento de pd-l1
CA3240346A1 (en) 2021-12-16 2023-06-22 Aligos Therapeutics, Inc. Methods and compositions for targeting pd-l1

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ264143A (en) 1993-08-09 1996-11-26 Lilly Co Eli Use of an aspartyl protease inhibitor to inhibit beta-amyloid peptide production
US7087399B1 (en) 1999-05-13 2006-08-08 Scios, Inc. β-secretase and modulation of β-secretase activity
EP1196609A2 (en) 1999-06-28 2002-04-17 Oklahoma Medical Research Foundation Catalytically active recombinant memapsin and methods of use thereof
MXPA03011399A (es) * 2001-06-08 2004-07-01 Elan Pharm Inc Metodos para tratar la enfermedad de alzheimer.
EP1453516A2 (de) 2001-10-17 2004-09-08 Boehringer Ingelheim Pharma GmbH & Co.KG 5-substituierte 4-amino-2-phenylamino-pyrimdinderivate und ihre verwendung als beta-amyloid modulatoren
JP2005534614A (ja) * 2002-01-04 2005-11-17 イーラン ファーマスーティカルズ、インコーポレイテッド アルツハイマー病治療のための置換アミノカルボキサミド
AU2003299101A1 (en) * 2002-09-27 2004-04-19 Elan Pharmaceuticals, Inc. Compounds for the treatment of alzheimer's disease
CA2505098A1 (en) * 2002-11-12 2004-05-27 Merck & Co., Inc. Phenylcarboxamide beta-secretase inhibitors for the treatment of alzheimer's disease
US20050090449A1 (en) 2003-05-13 2005-04-28 Boehringer Ingelheim International Gmbh Novel statine derivatives for the treatment of Alzheimer's disease
CN100430377C (zh) * 2003-06-30 2008-11-05 麦克公司 用于治疗阿尔茨海默病的N-烷基苯基甲酰胺β分泌酶抑制剂
WO2005110422A2 (en) 2004-05-19 2005-11-24 Boehringer Ingelheim International Gmbh Treatment of diseases associated with altered level of amyloid beta peptides
WO2005113582A1 (en) 2004-05-22 2005-12-01 Boehringer Ingelheim International Gmbh Substituted ethane-1,2-diamines for the treatment of alzheimer's disease
WO2006050862A1 (en) 2004-11-10 2006-05-18 Boehringer Ingelheim International Gmbh Statine derivatives for the treatment of alzheimer's disease
WO2006050861A2 (en) 2004-11-10 2006-05-18 Boehringer Ingelheim International Gmbh Statine derivatives for the treatment of alzheimer's disease
CA2603404A1 (en) * 2005-03-30 2006-10-05 Boehringer Ingelheim International Gmbh Substituted 1,2-ethylendiamines, medicaments comprising said compound; their use and their method of manufacture
CA2617294A1 (en) 2005-08-03 2007-02-08 Boehringer Ingelheim International Gmbh Substituted ethane-1,2-diamines for the treatment of alzheimer's disease ii
CA2618019A1 (en) 2005-08-11 2007-02-15 Boehringer Ingelheim International Gmbh Compounds for the treatment of alzheimer's disease

Also Published As

Publication number Publication date
US20090325940A1 (en) 2009-12-31
US20060223759A1 (en) 2006-10-05
TW200716152A (en) 2007-05-01
EP1866034A1 (en) 2007-12-19
JP2008534541A (ja) 2008-08-28
US20100204160A1 (en) 2010-08-12
CA2603404A1 (en) 2006-10-05
US7713961B2 (en) 2010-05-11
WO2006103038A1 (en) 2006-10-05

Similar Documents

Publication Publication Date Title
AR056862A1 (es) 1,2-etilendiaminas sustituidas, medicamentos que contienen a estos compuestos, su uso y procedimiento para su preparacion
UY33961A (es) Compuestos de bis(fuoroalquil)-1,4-benziodiazepinona
ECSP045476A (es) Tiazolidinonas, su preparación y su uso como medicamentos
UY32978A (es) Derivados de la cromenona
CR8649A (es) Derivados de formamidina para el tratamiento de enfermedades
MA31117B1 (fr) Composes tricycliques et leur utilisation comme modulateurs du recepteur de glucocorticoïdes
CO6561821A2 (es) Compuesto n-(1h-indazol-4-il)imidazol[1.2-a]piridin -3-carboxamida sustituidos como inhibidores de cfms
CO6280401A2 (es) Agonistas novedosos de los receptores de glucocorticoides
AR067107A1 (es) Derivados de tiazol[5,4-b]piridin moduladores de sirtuinas
EA201171098A1 (ru) 8-замещенные хинолины и родственные аналоги в качестве модуляторов сиртуина
PA8604201A1 (es) Derivados de 2-amino-piridina utiles para el tratamiento de enfermedades
BRPI0515546A (pt) compostos para inflamação e usos imune-relacionados
CU20090184A7 (es) Compuestos amino-heterocíclicos
AR090712A1 (es) Agentes para tratar trastornos que implican la modulacion de receptores de rianodina
AR077413A1 (es) Derivados piridin-4-ilo
CO6321241A2 (es) Derivados de 1,3,4- tiadiazol espiro condensados para la inhibicion de la actividad de quinesina (ksp)
AR056560A1 (es) Pirrolopiridinonas como moduladores cb1
SV2006002098A (es) Compuestos de morfolina sustituida para el tratamiento de trastornos del sistema nervioso central ref. pc32250a
AR047529A1 (es) Compuestos de quinolina sustituidos
CY1108230T1 (el) Παραγωγα 2-(1η-ινδολυλοσουλφανυλ)-βενζυλαμινης ως ssri
EA200700909A1 (ru) Азаиндолкарбоксамиды
PA8779101A1 (es) "compuestos tricíclicos como inhibidores de metaloproteinasas matriciales"
EA201000362A1 (ru) Производные 1,3-дигидроизоиндола
CL2011001050A1 (es) Compuesto 2-metil-1-(fenilsulfonil)-4-(piperazin-1-il)-1h-bencimidazol, que es ligando de 5-hidroxitriptamina-6; su composicion farmaceutica; modulador de la actividad de 5-ht6; su uso en el tratamiento de trastornos del sistema nervioso central, tal como psicosis, ansiedad, depresión, epilepsia, entre otros.
PA8627001A1 (es) Compuestos para el tratamiento de enfermedades

Legal Events

Date Code Title Description
FA Abandonment or withdrawal